1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
North America Non-Invasive Aesthetic Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Procedure and End User

North America Non-Invasive Aesthetic Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Procedure and End User

  • July 2021
  • 148 pages
  • ID: 6134747
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The North America non-invasive aesthetic treatment market is expected to reach US$ 8,085.74 million by 2028 from US$ 3,126.34 million in 2021; it is estimated to grow at a CAGR of 14.5% from 2021 to 2028. The growth of the market is attributed to a few key driving factors such as rising number of non-invasive aesthetic/cosmetic procedures performed every year and surging awareness about cosmetic procedures among consumers. However, clinical risks and complications associated with medical aesthetic procedures is hindering the market growth.
Non-invasive aesthetic treatments have gained popularity in the past few years due to advantages such as minimal downtime, no scars, low cost, and less complications.The popularity and acceptance of these procedures is mainly attributed to their non-invasiveness.

Besides, it has been proved that the accuracy rate of minimally invasive surgeries is greater than that of open surgeries.Therefore, the advantages of minimally invasive procedures over conventional surgery—such as faster recovery, reduced pain, and shortened hospital stays, and greater efficiency rate—contribute to the non-invasive aesthetic treatment market growth.

As per the American Society for Aesthetic Plastic Surgery (ASAPS), in 2018, ~3.8 million minimally invasive cosmetic operations were performed in the US in people with age 55 and above. The advancements in nonsurgical technologies and unveiling of new surgery options have made aesthetics accessible to people. For example, the advantages of laser procedures have attracted younger people to improve their skin conditions, modify body parts, and correct their physical posture. Therefore, rising acceptance of non-invasive aesthetic/cosmetic procedures is driving the growth of the North America non-invasive aesthetic treatment market. Several government initiatives are helping in creating awareness regarding non-invasive aesthetic procedures among people, which is also boosting the market growth.
North America is highly affected due to the COVID-19 outbreak pandemic.In the US, due to an increasing number of infected patients, healthcare professionals and leading organizations distract the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation.

In addition, the COVID-19 pandemic is perplexing healthcare institutions in the region with unprecedented operational and clinical challenges with diagnostics and bed availability. Moreover, high priorities for the diagnosis and treatment of COVID-19 are leading to decline in non-invasive aesthetic treatment, which is restraining the growth of the North America non-invasive aesthetic treatment market up to certain extent.
The North America non-invasive aesthetic treatment market, based on procedure, is segmented into injectables, skin rejuvenation, and others. The injectables segment held the largest share of the market in 2020, and the market for the same segment is expected to grow at the fastest rate during the forecast period.
The North America non-invasive aesthetic treatment market, by end user, is segmented into hospitals, clinics and medical spas, and others.The hospitals segment held the largest share of the market in 2020.

Also, the same segment is anticipated to register the highest CAGR in the market during the forecast period.
A few of the major primary and secondary sources referred to while preparing the report on the North America non-invasive aesthetic treatment market are the American Society for Aesthetic Plastic Surgery (ASAPS), Modern Aesthetics by American Medical Spa Association (AmSpa), and Canadian Board of Aesthetic Medicine (CBAM).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030

  • $ 5000
  • September 2021
  • 175 pages

Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis ...

  • World
  • United Kingdom
  • Biosimilar
  • Chronic Disease
  • Industry analysis
  • Drug Approval
  • Biosimilar Sales

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on